1056PEstimated costs of treatment-related adverse events (TRAEs) for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the checkmate 141 trial. (18th September 2017) - Venkatachalam, M.; Bobiak, S.; Shaw, J.W.; Santi, I.; Contente, M.; Korytowsky, B.; Stenehjem, D.D.